Cardiol Therapeutics surprises investors with a significant earnings beat, showcasing resilience in a challenging sector.
On August 13, 2026, Cardiol Therapeutics Inc Class A (CRDL.TO) reported its latest earnings, revealing an EPS of -$0.05, surpassing analysts' expectations by 50%. This performance highlights the company's ongoing efforts in the pharmaceutical industry, particularly in addressing pericarditis through its innovative CardiolRx™ treatment.
Recent earnings trend
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeAdvertisement
Market cap
$244.38M
52W high
$2.45
52W low
$1.23
1W change
+25.39%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 147.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+147.9% Upside
Current Price
C$2.42
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
69.7%
Annualized
90-Day Vol
60.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.89
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.57 | C$2.02 – C$3.27 |
| 60 trading days | C$2.73 | C$1.94 – C$3.83 |
| 90 trading days | C$2.89 | C$1.91 – C$4.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 3 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | — | -0.1000 | — |
| 2026-06-30 | 2026-08-13 | -0.0500 | -0.1000 | +50.0% |
| 2026-03-31 | 2026-05-12 | -0.0719 | -0.0900 | +20.1% |
| 2025-12-31 | 2026-03-31 | -0.0700 | -0.1100 | +36.4% |
| 2025-09-30 | 2025-11-13 | -0.1200 | -0.1000 | -20.0% |
| 2025-06-30 | 2025-08-14 | -0.1000 | -0.1200 | +16.7% |
Advertisement
Investor takeaway: Investors should note Cardiol's recent earnings beat as a positive indicator of its operational stability and growth potential, especially in light of its ongoing clinical trials and recent publication in a prominent medical journal.
Earnings Surprise of 50% Reflects Positive Momentum
Cardiol's EPS of -$0.05, compared to an estimate of -$0.10, marks the third earnings beat in the last four quarters, showcasing a trend of improving performance amidst financial challenges.
Bull case
The strong earnings surprise shows that Cardiol is managing costs effectively while pushing forward with its clinical programs. Analysts are optimistic, and with significant upside potential to average price targets, the company could attract continued investor interest as it advances its research and development.
Bear case
Even with the earnings beat, Cardiol is still facing financial challenges, with a trailing twelve-month EPS of -0.39 and no profit margin. Investors should be aware of the risks tied to pharmaceutical developments and the competitive landscape.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
